We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00981903
Recruitment Status : Terminated (Tinzaparin will no longer be available in the United States)
First Posted : September 22, 2009
Last Update Posted : July 6, 2017
Celgene Corporation
Information provided by (Responsible Party):
University of Southern California

Brief Summary:
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism Cancer Drug: Tinzaparin sodium Phase 2

Detailed Description:
The purpose of this study is to use long-term administration of a low molecular weight heparin (tinzaparin) for primary treatment and secondary prophylaxis of venous thromboembolism in patients with cancer. We will determine the efficacy (recurrent VTE) and safety (major hemorrhage) of this approach. Secondarily, we will analyze the outcome of patients in terms of survival and response to therapy versus matched controls. We will also determine baseline levels of markers of hemostasis, fibrinolysis, and angiogenesis and will follow changes with treatment as well as correlate levels of these plasma markers with outcomes, including recurrent venous thromboembolism, major hemorrhage,and survival.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 131 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
Study Start Date : July 2005
Primary Completion Date : October 2012
Study Completion Date : October 2015

Arm Intervention/treatment
Experimental: VTE Treatment Group Drug: Tinzaparin sodium
Subcutaneous injection 175 U/Kg/day
No Intervention: Control

Primary Outcome Measures :
  1. Development of recurrent venous thromboembolism and major hemorrhage. [ Time Frame: up to 6 months on treatment ]

Secondary Outcome Measures :
  1. Secondary outcome measures will evaluate other thrombotic events, clinical cancer outcome, and plasma markers of hemostasis, fibrinolysis, and angiogenesis [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of active cancer
  • Patients have documented or recurrent malignancy and must meet at least one of the following criteria:

    • Diagnosis or documented presence of cancer within 6 months, excluding squamous cell or basal cell carcinoma of the skin OR
    • Receive any therapy for cancer within the previous 6 months OR
    • Currently receiving any treatment (surgery, radiation, chemotherapy, hormonal therapy, biotherapy, palliative therapy, and/or combined modality therapy) for cancer
  • Documented first venous thromboembolic event
  • Patients must meet at least one of the following criteria:

    • Deep vein thrombosis of the lower extremity confirmed with duplex ultrasonography, magnetic resonance imaging, or venogram OR
    • Pulmonary embolism confirmed with high probability V/Q scan, CT angiogram, or pulmonary angiogram
  • ECOG performance status of 0, 1, or 2
  • Signed written informed consent
  • Age 18 years or greater

Exclusion Criteria:

  • Body weight less than 40 kg
  • Recurrent spontaneous fractures unrelated to the underlying active malignancy
  • Administration of therapeutic doses of unfractionated or low molecular weight heparin for more than 48 hours prior to registration Amendment 3 (05/26/2009) 11
  • Need for long-term oral anticoagulant therapy (e.g., mechanical heart valves, atrial fibrillation)
  • Poor performance status with an ECOG score of 3 or 4
  • Serious hemorrhage requiring hospitalization, transfusion, or surgical intervention within 2 weeks of presentation
  • Known acute (symptomatic or active bleeding) gastroduodenal ulcer
  • Epidural/spinal puncture within the last 24 hours
  • Neurosurgery within 1 week of registration or any previous history of intracranial hemorrhage
  • Septic endocarditis
  • Overt pericardial effusion
  • Current platelet count of less than 50 x 109/L
  • Undergoing high dose chemotherapy for peripheral blood stem cell or bone marrow transplantation, induction chemotherapy for acute leukemia, or has other conditions associated with persistent thrombocytopenia of less than 100 109/L for a duration of at least four consecutive weeks
  • Familial bleeding diathesis
  • Uncontrolled hypertension despite antihypertensive therapy
  • Dependent upon renal dialysis or significant renal failure with a serum creatinine of greater than three times the upper limit of normal
  • Allergy to heparin (unfractionated or low molecular weight)
  • Allergy to contrast medium
  • Pregnant or of childbearing potential and not using adequate contraception
  • Geographically inaccessible for follow-up
  • Failure or inability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981903

United States, California
University of Southern California
Los Angeles, California, United States, 90033
United States, New York
Cornell Weill Scholl of Medicine
New York, New York, United States, 10021
Sponsors and Collaborators
University of Southern California
Celgene Corporation

Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT00981903     History of Changes
Other Study ID Numbers: 0S-04-5
First Posted: September 22, 2009    Key Record Dates
Last Update Posted: July 6, 2017
Last Verified: July 2017

Keywords provided by University of Southern California:
VTE in cancer patients

Additional relevant MeSH terms:
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action